• Editing LDL at Its Source: The Promise of VERVE-102

    Editing LDL at Its Source: The Promise of VERVE-102

    VERVE-102 uses base editing to switch off PCSK9 production within liver cells after one intravenous infusion. In an early trial, the highest dose lowered LDL cholesterol by 62%, approaching results achieved with today’s strongest PCSK9 treatments. However, approved injections have far more safety experience and proven cardiovascular benefits. This patient-friendly review explains the promise, practical advantages, limitations, and unanswered questions surrounding this potentially lasting treatment.

    Categorized as , , ,